Dr. Susan Galbraith

We've seen that, if you like, in the Himalaya study with the stride regimen in hepatocellular carcinoma.

But we also know that bladder cancer is one of the most

CTLA-4 sensitive tumor types.

So we hope that that will translate through to a further improvement in the long-term outcomes of event-free survival because inhibiting CTLA-4 when the tumor's there and you've got the kind of mechanism of cell kill, immunogenic cell kill,

from a treatment with an ADC like the fortimanfidozin, that you can get really good priming of the immune response and that that can translate through to very good long-term outcomes.

So there's two different reasons why it's different from the EV905 study, but I think the data that is seen gives us a high degree of confidence that we can hit the pathologic complete response endpoint in the Volga study and that that also then translates through to the important...

endpoints of event-free survival and ultimately for overall survival.

All right.

So I think in the context of bladder cancer, I don't think that PD-L1 is as predictive as it is in some other.

Well, I mean, I think you've seen with Niagara that in the context of this perioperative setting, we really have very good data that's led to an improvement in the event-free survival context for Niagara.

So, you know, we now have three perioperative regimens with divalumab.

Matterhorn, Aegean, and Niagara, where we've all seen very robust effect sizes and the event survival effect sizes is similar across the class.

So I'm not sure that there is differentiation across that PD-L1 versus PD-1.

Okay.

So we will provide an update at the Q3 results on the timing for the Volga study.

Well, I mean, I think it's going to be very clear that given the data that we've seen that there's an opportunity for the EV regimen to move into the early line.

And so I think there's going to be an opportunity for wanting to have alternative treatments in the

in the metastatic setting for those patients.

The vast majority of patients that are diagnosed with body cancer are diagnosed, you know, not de novo metastatic, but in the muscle invasive or non-muscle invasive setting first before they progressed to metastatic disease.

So I think this is going to come up as a question and having a different target and a different mechanism of action of payload will be an important option for patients with body cancer.